To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Multi-site Efficacy and Safety Trial of Intrapartum Azithromycin in Low- and Middle-Income Countries

This study will test whether an antibiotic taken during labor can prevent infections in mothers and newborns in seven low- and middle-income countries. It will be conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) through their Global Network for Women’s and Children’s Health Research (Global Network) in partnership with the Bill & Melinda Gates Foundation.

CarMollNat Muscular Dystrophy Endowment

Carol-Ann Harris has established the CarMollNat Endowment in memory of her beloved family members. The Endowment is committed to support research and science for the major forms of Muscular Dystrophy (MD) and neurogenetic disease.

The Moderate Alcohol and Cardiovascular Health Trial (MACH15)

The Moderate Alcohol and Cardiovascular Health Trial (MACH15) was a longitudinal, international clinical trial to determine the effects of moderate alcohol use on cardiovascular disease and diabetes. 

Accelerating Medicines Partnership - Parkinson's Disease

In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community.

The Biomedical Research Community Responds to the Opioids Crisis

As part of a larger national effort to address the opioid crisis, the FNIH is leading the planning effort for a potential public-private scientific partnership that includes the NIH, FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA) and more than 30 biopharmaceutical companies.

Plasticity and Mechanisms of Cognitive Remediation in Older Adults

Plasticity and Mechanisms of Cognitive Remediation in Older Adults supports a grant for a multicenter clinical research trial on remediating age-related cognitive decline through mindfulness-based stress reduction and exercise.

Accelerating Medicines Partnership - Alzheimer's Disease

The Accelerating Medicines Partnership Alzheimer’s Disease Project (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets. 

The NIH Undiagnosed Diseases Program

The Undiagnosed Diseases Program (UDP) at the National Institutes of Health assists with diagnosing patients who have long been unable to find any diagnosis for their symptoms.

Accelerating Medicines Partnership (AMP)

The goal of the Accelerating Medicines Partnership (AMP) is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment.

Clinical Center Drug Donations

The Clinical Center In-Kind Drug Donation Program provides pharmaceuticals that are donated through the public-private partnership coordinated by the FNIH to the NIH Clinical Center.